Therapies

Seattle Genetics Lands $1.72B From Merck in Pair of Cancer Drug Deals

8 days ago   |   By Xconomy

Seattle Genetics is in line to receive $1.72 billion from Merck via a pair of deals , one for a cancer drug that's still in development and the other for partial rights to a therapy that won FDA approval earlier this year. The larger of the two deals is for the drug still in clinical development, ladiratuzumab vedotin. According to terns announced Monday, the two companies have agreed to jointly develop that drug, both by itself and in combination with Merck blockbuster cancer drug pembrolizumab. The deal calls for Merck to pay Bothell, WA-based SeaGen (NASDAQ: SGE...
Read more ...

 


Search by Tags

   Therapies      Drugs      Drug      Clinical      Cancer      Genetics      NASDAQ      National blog main      National top stories      New York blog main      New York top stories      Seattle      Seattle blog main      Seattle top stories      Antibody Drug Conjugate      AstraZeneca      Biotech      Brentuximab Vedotin      Cancer Drugs      Clay Siegall      Clinical trials      Daiichi Sankyo      Deals      Enfortumab Vedotin      FDA      Gilead Sciences      GlaxoSmithKline      Immunomedics      Ladiratuzumab vedotin      Life Sciences      Merck      Pembrolizumab      Sacituzumab govitecan      Seattle Genetics      Takeda Pharmaceutical      Trastuzumab deruxtecan  


World Biotechnology Congress 2019

Hilaris Conferences is going to host its premier World Biotechnology Congress 2019 during October 01-02, 2019, Valencia, Spain. Biotechnology 2019 Congress aim to create a... Read more ...

World Biotechnology Congress 2019

Hilaris Conferences is going to host its premier World Biotechnology Congress 2019 during October 01-02, 2019, Valencia, Spain. Biotechnology 2019 Congress aim to create a... Read more ...

2nd International Conference on Tissue Science and Regenerative Medicine

This conference is designed for experts in academia and industries working in the tissue science and regenerative field, this conference will examine cutting-edge research in... Read more ...

Berkeley Team Plays Key Role in Analysis of Particle Interactions That...

Berkeley Team Plays Key Role in Analysis of Particle Interactions That Produce Matter From Light

This image shows a reconstruction of a particle event at CERN's ATLAS detector that produced W bosons from photons, which are particles of light. Researchers at the U.S... Read more ...

Tau-Targeting Alzheimer's Drug from AC Immune, Roche Fails in Phase 2

Tau-Targeting Alzheimer's Drug from AC Immune, Roche Fails in Phase 2

An Alzheimer's disease drug from partners AC Immune and Roche has failed a mid-stage clinical trial, adding another compound to the list of experimental therapies that have... Read more ...

Athira CEO Kawas: Alzheimer's Drug Aims for “Recovery of Brain Function”

Athira CEO Kawas: Alzheimer's Drug Aims for “Recovery of Brain Function”

The key to Athira Pharma's approach to Alzheimer's disease is already inside each of us: a repair mechanism that can regenerate damaged neurons. What's needed to begin the... Read more ...

Gene Therapy Firms Seek Clarity on FDA Exclusivity, Orphan Designations

Gene Therapy Firms Seek Clarity on FDA Exclusivity, Orphan Designations

Gene therapy product developers are seeking more clarity from the US Food and Drug Administration on when viral vectors from the same class will be considered sufficiently... Read more ...

Checkmate, Chromosome 8: The First End-to-End Sequence of a Human Autosome

Checkmate, Chromosome 8: The First End-to-End Sequence of a Human Autosome

Even in the field of genomics where new breakthroughs occur every few months, completion of the first-ever fully sequenced human autosome is a momentous achievement. Highly... Read more ...

Senior Analyst/Programmer II - Remote Role

The primary responsibilities of this position will be to lead database or statistical programming activities and provide end to end programming support in planning, specifying... Read more ...

Knockoff Boosted Tree for Model-Free Variable Selection

AbstractMotivationThe recently proposed knockoff filter is a general framework for controlling the false discovery rate when performing variable selection. This powerful new... Read more ...

IsoResolve: Predicting Splice Isoform Functions by Integrating Gene and...

AbstractMotivationHigh resolution annotation of gene functions is a central goal in functional genomics. A single gene may produce multiple isoforms with different functions... Read more ...

Bedtk: Finding Interval Overlap with Implicit Interval Tree

AbstractSummaryWe present bedtk, a new toolkit for manipulating genomic intervals in the BED format. It supports sorting, merging, intersection, subtraction and the calculation... Read more ...

Prioritizing transcriptomic and epigenomic experiments by using an...

AbstractMotivationSuccessful science often involves not only performing experiments well, but also choosing well among many possible experiments. In a hypothesis generation... Read more ...